Shire News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.10.18	Form 8.3 - The Vanguard Group, Inc.: Shire plc (EQS Group)
11.10.18	Form 8.3 - The Vanguard Group, Inc.: Shire plc (EQS Group)
21.09.18	Shire Receives Approval of FIRAZYR® (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan (GlobeNewswire)
20.09.18	Health Canada has authorized TAKHZYRO(TM) (lanadelumab injection), a first-of-its-kind monoclonal antibody treatment for the prevention of hereditary angioedema (HAE) attacks (GlobeNewswire)
12.09.18	Shire Granted EU Marketing Authorization for Veyvondi® for Adults With Von Willebrand Disease (GlobeNewswire)
10.09.18	SHIRE ANNOUNCES THE PRICING TERMS AND INCREASE IN THE MAXIMUM TENDER AMOUNT OF THE PREVIOUSLY ANNOUNCED CASH TENDER OFFERS FOR CERTAIN OUTSTANDING NOTES (GlobeNewswire)
10.09.18	SHIRE ANNOUNCES EARLY RESULTS OF THE PREVIOUSLY ANNOUNCED CASH TENDER OFFERS FOR CERTAIN OUTSTANDING NOTES (GlobeNewswire)
06.09.18	Shire Acquires sanaplasma AG Boosting Plasma Collection Network for Immunology Franchise (GlobeNewswire)
31.08.18	Shire Completes Sale of Oncology Franchise (GlobeNewswire)
24.08.18	SHIRE ANNOUNCES CASH TENDER OFFERS FOR UP TO $2,250,000,000 OUTSTANDING PRINCIPAL AMOUNT OF NOTES (GlobeNewswire)
24.08.18	Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema (GlobeNewswire)
13.08.18	New Drug Application Submitted in Japan for INTUNIV® (guanfacine hydrochloride extended release) in Adults with ADHD (GlobeNewswire)
22.06.18	Shire plc: Large-Scale European Review Suggests Disparity in Symptom Recognition and Standardized Treatment for Metastatic Adenocarcinoma of the Pancreas (GlobeNewswire)
21.06.18	Shire Receives U.S. FDA Approval for New State-of-the-Art Plasma Manufacturing Facility Near Covington, Georgia (GlobeNewswire)
21.06.18	Shire Announces FDA Approval for Label Expansion of CINRYZE® for Prevention of Attacks in Pediatric HAE (GlobeNewswire)
22.05.18	Shire announces new hypoparathyroidism data at the 2018 European Congress of Endocrinology (GlobeNewswire)
25.04.18	Shire plc : Shire announces revised proposal and extension of PUSU deadline to 8 May 2018 (GlobeNewswire)
20.04.18	Shire plc : Statement re Proposal from Takeda Pharmaceutical Company Limited (GlobeNewswire)
19.04.18	Shire plc : Statement re Proposal from Takeda Pharmaceutical Company Limited (GlobeNewswire)
16.04.18	Shire plc : Shire Announces Sale of Oncology Business to Servier for $2.4 Billion (GlobeNewswire)
29.03.18	Shire Reports Regulatory Milestones for Investigational Hereditary Angioedema (HAE) Treatment Lanadelumab (GlobeNewswire)
26.03.18	Shire and NanoMedSyn Enter Into Research Agreement for Potential Lysosomal Storage Disorder Treatment (GlobeNewswire)
20.03.18	Shire plc : New Data Presented at the Endocrine Society's 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism (GlobeNewswire)
12.03.18	Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society's 2018 Annual Meeting (GlobeNewswire)
27.02.18	The EMA Grants Accelerated Assessment for Shire's Lanadelumab Being Evaluated for the Prevention of Attacks in HAE Patients Aged 12 Years and Older (GlobeNewswire)
22.02.18	Shire Recognizes Rare Disease Day 2018 with Global Initiatives Focused on Reducing the Time to Diagnosis (GlobeNewswire)
30.01.18	AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program (GlobeNewswire)
24.01.18	FDA Grants Approval to Shire for Technology Transfer of CINRYZE® Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site (GlobeNewswire)
08.01.18	Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
04.01.18	Shire to present at the 36th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
27.12.17	Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise (GlobeNewswire)
13.12.17	Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire)
05.12.17	Shire and Rani Therapeutics Enter into Collaboration to Evaluate Use of the Rani Pill(TM) Technology for the Oral Delivery of Factor Therapy (GlobeNewswire)
01.12.17	Shire Appoints Andreas Busch, Ph D as Head of Research and Development and Chief Scientific Officer (GlobeNewswire)
30.11.17	U.S. FDA Grants Shire Orphan Drug Designation for Investigational Anti-MAdCAM Antibody SHP647 for the Treatment of Moderately to Severely Active Ulcerative Colitis in Pediatric Patients (GlobeNewswire)
20.11.17	Shire plc : Directorate change (GlobeNewswire)
13.11.17	CHMP recommends EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia A (GlobeNewswire)
10.11.17	Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology (GlobeNewswire)
26.10.17	Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients (GlobeNewswire)
25.10.17	Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A (GlobeNewswire)
13.10.17	Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire)
20.09.17	Shire and Shionogi Announce Positive Topline Results for INTUNIV® Evaluated in Phase 3 Clinical Trial in Adults with ADHD (GlobeNewswire)
12.09.17	Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants (GlobeNewswire)
11.09.17	Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial (GlobeNewswire)
07.09.17	Shire to participate at two upcoming investor conferences (GlobeNewswire)
22.08.17	Shire plc : Director/PDMR Shareholding (GlobeNewswire)
21.08.17	Shire plc Director and Senior Management Changes (GlobeNewswire)
15.08.17	Shire announces submission of lifitegrast Marketing Authorization Application for treatment of dry eye disease in Europe (GlobeNewswire)
30.03.09	Hugin-News: Jerini AG (GlobeNewswire)
05.10.06	Hugin-News: Jerini AG (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

27.11.24		Minuszeichen in New York: Dow Jones beendet die Sitzung im Minus
27.11.24		Dow Jones aktuell: Dow Jones legt nachmittags den Rückwärtsgang ein
27.11.24		Schwacher Wochentag in New York: Dow Jones verliert am Mittwochmittag
27.11.24		Mittwochshandel in London: FTSE 100 legt zum Handelsende zu
27.11.24		STOXX 50 aktuell: STOXX 50 zeigt sich zum Handelsende schwächer
27.11.24		Mittwochshandel in Zürich: SPI klettert schlussendlich
27.11.24		Schwacher Handel: SLI zum Handelsende im Minus
27.11.24		Schwache Performance in Europa: Euro STOXX 50 gibt letztendlich nach

27.11.24

Minuszeichen in New York: Dow Jones beendet die Sitzung im Minus

27.11.24

Dow Jones aktuell: Dow Jones legt nachmittags den Rückwärtsgang ein

27.11.24

Schwacher Wochentag in New York: Dow Jones verliert am Mittwochmittag

27.11.24

Mittwochshandel in London: FTSE 100 legt zum Handelsende zu

27.11.24

STOXX 50 aktuell: STOXX 50 zeigt sich zum Handelsende schwächer

27.11.24

Mittwochshandel in Zürich: SPI klettert schlussendlich